Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
- WORLD NEWS IN BRIEF
April 2, 2001
- Most municipal Hospitals Have Anti-Accident Manuals: JMHA Survey
April 2, 2001
- Major Japanese firms Aiming at 20% of Total Sales Overseas in 2005: JPMA Report
April 2, 2001
- MRSA Infections Found in 0.55% of Inpatients: Korosho Survey
April 2, 2001
- Final Draft of Ethical Guidelines for Human Genome Research Approved
April 2, 2001
- Sankyo Ties Up with Menarini to Market CS-866 in Europe
April 2, 2001
- 'Number System' Proposed for Social Security
April 2, 2001
- Celera to Acquire Minority Interest in HuBit Genomix
April 2, 2001
- Radicut, Herceptin, Zyvox Approved by CDFS
April 2, 2001
- DIAGNOSTIC NEWS IN BRIEF
April 2, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- AIN PHARMACIEZ Issues Membership Cards
April 2, 2001
- 18.6% of Inpatients Can Be Discharged: Survey
April 2, 2001
- Sales of OTC Drugs in FY2000 Likely to Drop Due to Poor Prevalence of Flu
April 2, 2001
- Percentage of Deficit-ridden Hospitals Declines Slightly: NHFJ Survey
April 2, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…